Diabetes, hypertension, cardiovascular diseases, cancer, osteoporosis and neurodegenerative diseases have one thing in common: they are often linked to the dysfunction of membrane proteins such as ion channels and transporters. A broad pathophysiological, biochemical and structural knowledge of these proteins will open the door to rational, ligand-based drug design.

In the late 1980th, working together with Ernest M. Wright at the University of Los Angeles, CA, USA, Hediger developed the expression cloning technique for membrane transport proteins (Hediger et al., Nature 1987 330:379-81 and Hediger et al., Methods Enzymol. 1998 296:17-52). Using this technique, he identified and characterized various transport proteins, including transporters of iron, vitamin C, urea, citrate, glutamate, dibasic amino acids and peptides, as well as epithelial calcium channels. In addition,  he investigated their physiological implications in major human diseases.

Hediger has obtained patent protection on several commercially important transporters. In recognition of his work, he received the 2004 Rank Prize in Nutritional Sciences (Surrey, UK) and the 2009 Japanese Society for the Study of Xenobiotics Award (Kyoto, Japan).

To promote the transporter field in the biomedical and pharmaceutical areas, Hediger has established two international conference series:

1. The International Gordon Research Conference Series on the physiological and pathological aspects of transporters
2. The International BioMedical Transporter Conference Series on the pharmaceutical aspects of transporters.

In addition, he edited a special issue in the Pflügers Archiv - European Journal of Physiology entitled "The ABC's of solute carriers" (2004, Vol. 447) which features the first systematic summary of the biomedical aspects of all classical transporter families. He then established a web-based genomic resource of the HUGO approved transporter families (www.bioparadigms.org).

Hediger has completed numerous corporate-sponsored research projects with international pharmaceutical companies and maintains a broad network across the university boundary.

Currently, Hediger is focussing on pharmaceutically attractive transport proteins, such the epithelial calcium channels TRPV5 and TRPV6, the vitamin C and nucleobase transporters SVCT1, SVCT2 and SVCT3 and various transporters of metal ions. His premise is that integration of physiology, pathology, structural biology and chemistry will be tremendously beneficial in accelerating the translational avenue from "gene to drug".

This avenue should include the elucidation of the atomic structures of the ligand- and drug binding sites in order to design therapeutic drugs that bind selectively and with high specificity to target membrane proteins.

Personal Website
Hediger Group